杭州浙大迪迅生物基因工程有限公司Release date：2018-12-18
JACI:
DOI: https://doi.org/10.1016/j.jaci.2017.12.843 Abstract:
Background
Rationale
Soy allergy is one of the most common food allergies. The presence of IgE specific to soy component storage proteins Gly m4, m5, and m6 has been indicated as a means to improve the specific identification of systemic and local soy allergic reactions.
Methods
A retrospective review of national laboratory data was performed over samples testing for IgE to Gly m4, 5, and 6 (Phadia ImmunoCAP). Data from de-identified patient samples were compiled into risk groups based on current research utilizing the international standard cutoff of 0.35kU/L as a positive test for IgE.
Results
Of the sample set, 46% of patients were responsive to at least one soy component. Of these, 39% of patients display response to only Gly m5 and 6, the components most indicative of a severe and systemic response to soy. Patients responsive to Gly m4 only represented 37%, and 15% were responsive to all components. Few patients were responsive to Gly m5 or 6 separately or associated with Gly m4. Nearly 60% of positive pediatric (<10Y) patients were responsive to both Gly m5 and 6 and only 14% to Gly m4 alone. Patients older than 10 years predominantly respond to Gly m4 alone over m5 and m6 only (54% to 24%).
Conclusions
Molecular component allergy testing represents a major step forward in assessing risk of soy allergies and constructing an appropriate medical response. A significant rate of specificity between the identification of markers for systemic and local/non-specific reactions indicates the importance of this information for patients and their families.
All Author:
Dallas C. Jones, Amanda L. Hays Michelle L. Altrich PhD
[IF:13.1]
Analysis of Soy Allergy Using Molecular Component TestingDOI: https://doi.org/10.1016/j.jaci.2017.12.843 Abstract:
Background
Rationale
Soy allergy is one of the most common food allergies. The presence of IgE specific to soy component storage proteins Gly m4, m5, and m6 has been indicated as a means to improve the specific identification of systemic and local soy allergic reactions.
Methods
A retrospective review of national laboratory data was performed over samples testing for IgE to Gly m4, 5, and 6 (Phadia ImmunoCAP). Data from de-identified patient samples were compiled into risk groups based on current research utilizing the international standard cutoff of 0.35kU/L as a positive test for IgE.
Results
Of the sample set, 46% of patients were responsive to at least one soy component. Of these, 39% of patients display response to only Gly m5 and 6, the components most indicative of a severe and systemic response to soy. Patients responsive to Gly m4 only represented 37%, and 15% were responsive to all components. Few patients were responsive to Gly m5 or 6 separately or associated with Gly m4. Nearly 60% of positive pediatric (<10Y) patients were responsive to both Gly m5 and 6 and only 14% to Gly m4 alone. Patients older than 10 years predominantly respond to Gly m4 alone over m5 and m6 only (54% to 24%).
Conclusions
Molecular component allergy testing represents a major step forward in assessing risk of soy allergies and constructing an appropriate medical response. A significant rate of specificity between the identification of markers for systemic and local/non-specific reactions indicates the importance of this information for patients and their families.
All Author:
Dallas C. Jones, Amanda L. Hays Michelle L. Altrich PhD
2018-12-12 Article
Hangzhou Zheda Dixun Biological Gene Engineering Co., Ltd. Copyright HZKC Technical support 浙ICP备14005341号 （浙）-非经营性-2019-0050
Address: Rm.201-209, Bldg.2, No.568 Binkang Rd., Binjiang Dist. Tel: 0571-87968248-805 Website:www.zdbiogene.com
COPYRIGHT©2003-2024 www.zdbiogene.com CORPORATION. ALL RIGHTS RESERVED
Official WeChat